Paper Details

  1. Home
  2. Paper Details

Evaluation of efficacy and safety of ciprofloxacin ophthalmic solution versus chloramphenicol.

Author: BloomP A, CollumL M, EastyD L, LaidlawD A, LibertJ, PowerW J, SakselaT, SangersD, WuokkoM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Ciprofloxacin ophthalmic solution 0.3% is as safe and as effective as 0.5% chloramphenicol ophthalmic solution in the treatment of bacterial conjunctivitis and blepharitis.
Paper Details　
Original Abstract of the Article :
The results of this clinical study demonstrate that ciprofloxacin ophthalmic solution 0.3% is as safe and as effective as 0.5% chloramphenicol ophthalmic solution in the treatment of conjunctivitis and blepharitis of bacterial aetiology. Both agents achieved microbiological improvement rates in exce...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/112067219300300205

データ提供：米国国立医学図書館（NLM）

Ciprofloxacin: A New Oasis in the Desert of Bacterial Eye Infections

Bacterial eye infections, like a desert storm, can cause pain, redness, and impaired vision. This research investigates the effectiveness and safety of ciprofloxacin ophthalmic solution, a commonly prescribed antibiotic for bacterial eye infections, in comparison to chloramphenicol ophthalmic solution. The authors conducted a clinical study involving patients with conjunctivitis and blepharitis, finding that ciprofloxacin was equally effective and safe as chloramphenicol in treating these infections. They also noted that ciprofloxacin did not have the same risk of serious side effects as chloramphenicol, suggesting its potential as a preferred treatment option for bacterial eye infections.

Ciprofloxacin: An Effective and Safe Treatment for Bacterial Eye Infections

This research offers valuable insights into the effectiveness and safety of ciprofloxacin ophthalmic solution for treating bacterial eye infections. The authors' findings indicate that ciprofloxacin is equally effective as chloramphenicol in treating conjunctivitis and blepharitis, while carrying a lower risk of serious side effects. This suggests that ciprofloxacin could be a more favorable treatment option for these common infections.

Navigating the Desert of Eye Infections: Finding the Right Path

This research emphasizes the importance of choosing appropriate treatments for bacterial eye infections. By understanding the effectiveness and safety of various medications, healthcare professionals can guide patients toward the most appropriate treatment, minimizing the risk of complications and maximizing the potential for a full recovery.

Dr.Camel's Conclusion

This research provides a refreshing oasis of knowledge in the desert of bacterial eye infections, highlighting the effectiveness and safety of ciprofloxacin ophthalmic solution. The findings suggest that ciprofloxacin could be a more favorable treatment option compared to chloramphenicol, offering a potential path to faster and safer recovery from these common infections.

Date :
  1. Date Completed 1993-09-23
  2. Date Revised 2022-10-07
Further Info :

Pubmed ID

8353434

DOI: Digital Object Identifier

10.1177/112067219300300205

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.